SHOGUN LGD-4033 (Ligandrol) 10mg X 60 Units For Sale
SHOGUN LGD-4033 (Ligandrol) 10mg X 60 Units, commonly known as Ligandrol, is a selective androgen receptor modulator (SARM) designed to mimic the effects of testosterone, promoting muscle growth and bone health. Each unit contains 10 mg of LGD-4033, with 60 units per package.
Usage & Dosage:
While specific dosing protocols for non-medical use are not established, clinical trials have utilized the following regimens:
- Clinical Trial Dosage: Studies have administered daily doses ranging from 0.1 mg to 2 mg, with treatment durations between 3 to 12 weeks. For example, a phase 2 trial observed a 9.1% increase in lean body mass with a daily dose of 2 mg over 12 weeks.
Potential Side Effects:
As with all SARMs, the safety profile of LGD-4033 is not fully understood. Reported side effects include:
-
Hormonal Changes: Potential suppression of natural testosterone production, leading to hormonal imbalances.
- Lipid Profile Alterations: Possible decreases in high-density lipoprotein (HDL) cholesterol levels.
- Liver Enzyme Elevations: Elevated liver enzymes, indicating potential liver stress or damage.
- Other Effects: Headaches, dry mouth, and fatigue have also been reported.
Legal Status:
LGD-4033 is classified as a research chemical and is not approved by the FDA for human consumption. Its use is prohibited by the World Anti-Doping Agency (WADA) in competitive sports. Regulations may vary by region, so it’s essential to be aware of local laws and guidelines.
Important Notice:
SHOGUN LGD-4033 is sold for research purposes only and is not intended for human consumption. The information provided here is for educational purposes and should not be construed as medical advice. Always consult with a qualified healthcare professional before considering the use of any research chemical.
Given the limited human clinical data, individuals should approach the use of LGD-4033 with caution and be fully informed of potential risks and legal considerations.
Reviews
There are no reviews yet.